<unk>  is registered as a prescription drug in more than 70 countries for the treatment of post-menopausal osteoporosis to reduce the risk of vertebral and hip fractures. In the United States,<unk>  is not approved by the FDA. In the United Kingdom,<unk>  is prescribed under the National Health Service as a medicine for the treatment of post menopausal osteoporosis. 2 major phase III clinical studies, SOTI (Spinal Osteoporosis Therapeutic Intervention) and TROPOS (Treatment of Peripheral Osteoporosis), were started in 2000 to investigate the efficacy of<unk>  in reducing vertebral fractures and peripheral fractures, including hip fractures. In the 3 years results, reported in 2004,<unk>  showed significant reduction in vertebral fractures with 41% and hip fractures with 36% compared with patients treated with placebo. The efficacy was sustained in 5 years data. The 5 years data confirmed that<unk>  can reduce the vertebral fractures significantly no matter the risk factors of the osteoporotic women have. These include their age (80), bone mineral density (osteoporotic and osteopenia), prevalent fractures (0 prevalent fracture, 1–2 prevalent fractures and >2 prevalent fractures), symptomatic fractures, body mass index and smoking.<unk>  shows anti-fracture efficacy in very old elderly and osteopenic patients.
Strontium ranelate
Calcium carbonate
Potassium fluoride
Sodium stibogluconate
Ferrous tartrate
Sodium fluoride
Dimethyl methylphosphonate
Lanthanum carbonate